Chongqing Kerui Pharmaceutical

Chongqing Kerui Pharmaceutical (Group) Co., Ltd. is a large-scale pharmaceutical enterprise based in Chongqing, China, with a history spanning over a century. As a key subsidiary of Chongqing Chemical Medical Holdings (Group) Co., Ltd., the company integrates drug research, development, manufacturing, and sales. Its product portfolio covers a broad range of therapeutic areas, including infectious diseases, cardiovascular health, respiratory conditions, and ophthalmology, the latter through a significant joint venture with Japan's Santen Pharmaceutical. Kerui is recognized for its extensive manufacturing capabilities in chemical drugs and traditional Chinese medicines, and it is currently advancing a pipeline of innovative and generic products, such as prasugrel and various antibiotic combinations. The company is also investing heavily in intelligent manufacturing through a major relocation project to the Chongqing International Biological City.